Search Result

Results for "

NaV

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Na+/Ca2+ Exchanger (2) Sodium Channel (199) 5-HT Receptor (4) Adrenergic Receptor (1) Akt (2) Apoptosis (6) Arrestin (2) ATP Synthase (4) Autophagy (6) Biochemical Assay Reagents (1) Calcium Channel (8) CaMK (2) CD20 (1) CRAC Channel (2) Cytochrome P450 (1) Dipeptidyl Peptidase (1) Drug Derivative (2) Drug Intermediate (1) Drug Metabolite (2) Environmental Pollutants (3) ERK (2) Ferroptosis (4) GABA Receptor (3) Glutathione Peroxidase (4) HCN Channel (2) Histamine Receptor (1) iGluR (3) Insecticide (1) Isotope-Labeled Compounds (6) Melatonin Receptor (2) Mitophagy (4) Neurotensin Receptor (2) NOD-like Receptor (NLR) (4) P2X Receptor (2) PINK1/Parkin (4) Potassium Channel (12) Ras (1) Reactive Oxygen Species (ROS) (3) Reference Standards (13) Serotonin Transporter (2) Small Interfering RNA (siRNA) (3) TRP Channel (7)
By Research Areas:	Cancer (12) Cardiovascular Disease (16) Infection (5) Inflammation/Immunology (28) Metabolic Disease (1) Neurological Disease (185)
Oligonucleotides:	Human Pre-designed siRNA Sets (3) Antisense Oligonucleotides (5) siRNAs (3)

220

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: Sodium Channel NKCC Na+/HCO3- Cotransporter Na+/Ca2+ Exchanger Na+/K+ ATPase Na+/H+ Exchanger (NHE)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-112473

Grassofermata 10+ Cited Publications NaV-2729	Ras	Cancer
Grassofermata is a dual Arf1/Arf6 activation inhibitor. ADP ribosylation factors (Arfs) are members of the Arf family of GTP-binding proteins of the Ras superfamily.

HY-125079

DSP-2230 ANP-230	Sodium Channel	Cardiovascular Disease Neurological Disease
DSP-2230 is the orally active inhibitor for voltage-gated sodium channel that inhibits Nav1.7-, Nav1.8-, and Nav1.9-derived sodium currents with IC₅₀s of 7.1 μM, 11.4 μM and 6.7 μM, respectively. DSP-2230 can be used to improve neuropathic pain .

HY-16787

ICA-121431 4 Publications Verification	Sodium Channel	Cardiovascular Disease
ICA-121431 is a nanomolar potent and broad-spectrum voltage-gated sodium channel (Na_v) blocker, shows equipotent selectivity for human Na_v1.1 and Na_v1.3 subtypes with IC₅₀ values of 13 nM and 23 nM, respectively. ICA-121431 shows less potent inhibition of Na_v1.2 (IC₅₀=240 nM) and 1,000 fold selectivity against Na_v1.4, Na_v1.6, and the TTX-resistant human Na_v1.5 and Na_v1.8 channels (IC₅₀s >10 μM).

HY-147423

Zandatrigine 1 Publications Verification NBI-921352; XEN901	Sodium Channel	Neurological Disease
Zandatrigine (NBI-921352; XEN901) is a selective, orally active, voltage-gated sodium channel *Na_V1.6*/SCN8A inhibitor that can penetrate the blood-brain barrier. Zandatrigine inhibits sodium influx by non-covalently binding to the VSD4 structure of Na_V1.6, blocking the persistent and resuscitative currents under pathological conditions. Zandatrigine can reduce neuronal hyperexcitability and reduce epileptic seizures. Zandatrigine is 134-756-fold selective for other isoforms such as Na_V1.1 and Na_V1.2, and has minimal effect on Na_V1.1 expressed by inhibitory interneurons. Zandatrigine can be used to study Na_V1.6-mediated neuroexcitability diseases such as SCN8A-related developmental epileptic encephalopathy (SCN8A-DEE) and adult focal epilepsy .

HY-B0262

Methocarbamol 1 Publications Verification	Sodium Channel	Neurological Disease
Methocarbamol is an orally active central muscle relaxant and blocks muscular Nav1.4 channel. Methocarbamol reversibly affects voltage dependence of inactivation of Nav1.4 channel. Methocarbamol has the potential for muscle spasms and pain syndromes research .

HY-100345

AMTB hydrochloride 2 Publications Verification	TRP Channel	Neurological Disease Cancer
AMTB hydrochloride is a selective TRPM8 channel blocker. AMTB hydrochloride inhibits icilin-induced TRPM8 channel activation with a pIC₅₀ of 6.23. AMTB hydrochloride can be used for the research of the overactive bladder and painful bladder syndrome. AMTB hydrochloride is a non-selective inhibitor of voltage-gated sodium channels (Na_V) .

HY-101383

PF-01247324 1 Publications Verification	Sodium Channel	Neurological Disease
PF-01247324 is a selective and orally bioavailable *Na_v1.8* channel blocker with an IC₅₀ of 196 nM for recombinant human Na_v1.8 channel.

HY-16723

Funapide TV 45070; XEN402	Sodium Channel	Neurological Disease Inflammation/Immunology
Funapide (TV 45070; XEN402) is an orally active inhibitor of voltage-gated sodium channels (VGSC) in the peripheral nervous system with IC₅₀ values ??of 84 nM and 54 nM for *Nav1.5* and *Nav1.7*, respectively. Funapide has analgesic effects .

HY-112279

GNE-131	Sodium Channel	Neurological Disease
GNE-131 is a potent and selective inhibitor of human sodium channel *NaV1.7, with an IC₅₀* of 3 nM.

HY-143481

Nav1.8-IN-2	Sodium Channel	Neurological Disease Inflammation/Immunology
Nav1.8-IN-2 (compound 35A) is a *Nav1.8* voltage-gated sodium ion inhibitor with an IC₅₀ of 0.4 nM (HEK 293 cells). Nav1.8-IN-2 inhibits the activity of Nav1.8 voltage-gated sodium ion channels, mediates sodium ion influx in excitable cells, and is associated with the initiation and conduction of action potentials. Nav1.8-IN-2 can be used for research related to pain, cough, itching, etc .

HY-152166

NaV1.2/1.6 channel blocker-1	Sodium Channel	Neurological Disease
NaV1.2/1.6 channel blocker-1 is a potent NaV1.2/1.6 channel blocker, with IC₅₀s of 9.8 and 24.4 μM for rNaV1.6 and hNaV1.2, respectively. NaV1.2/1.6 channel blocker-1 can be used for the research of generalized epilepsy .

HY-157802

LTGO-33	Sodium Channel	Neurological Disease
LTGO-33 is a potent and selective voltage-gated sodium channel *NaV1.8* inhibitor. LTGO-33 inhibits NaV1.8 in the nM potency range and exhibits over 600-fold selectivity against human NaV1.1-NaV1.7 and NaV1.9. LTGO-33 exhibits state-independent inhibition with similar potencies on channels in the closed and inactivated conformations. LTGO-33 inhibits native TTX-R NaV1.8 currents in non-human primate and human DRG neurons, where it reduces action potential firing. LTGO-33 can be used for pain disorders research .

HY-N1847

3'-Methoxydaidzein	Sodium Channel	Neurological Disease
3'-Methoxydaidzein is a isoflavone and a Sodium Channel inhibitor. 3'-Methoxydaidzein inhibits subtypes NaV1.7, NaV1.8 and NaV1.3 with IC₅₀ of 181 nM, 397 nM, and 505 nM, respectively. 3'-Methoxydaidzein exerts analgesic activity by inhibiting voltage-gated sodium channels .

HY-12811

PF-04856264 1 Publications Verification	Sodium Channel	Neurological Disease
PF-04856264 is a potent and selective *Nav1.7* inhibitor, with IC₅₀s of 28, 131, 19, and 42 nM for human, mouse, cynomolgus monkey and dog Nav1.7, respectively. PF-04856264 has low potency against the rat Nav1.7 channel. PF-04856264 shows analgesic effect .

HY-13985

Nav1.7 inhibitor	Sodium Channel	Neurological Disease Inflammation/Immunology
Nav1.7 inhibitor (compound II), a sulfonamide, is a potent *Nav1.7* inhibitor. Nav1.7 inhibitor has the potential for a wide range of disorders, particularly pain, including acute pain, inflammatory pain and/or neuropathic pain .

HY-101789

Nav1.7-IN-3	Sodium Channel	Neurological Disease
Nav1.7-IN-3 is a selective, orally bioavailable voltage-gated sodium channel Nav1.7 inhibitor with an IC₅₀ of 8 nM. Pain relief. Limited CNS penetration .

HY-119934

NaV1.7 inhibitor-1	Sodium Channel	Neurological Disease
NaV1.7 inhibitor-1 is an efficacious *voltage-gated sodium channel (NaV) 1.7* inhibitor with an IC₅₀ of 0.6 nM for hNaV1.7, exhibits 80-fold selectivity versus hNaV1.5 .

HY-133910

Lu AE98134 1 Publications Verification	Sodium Channel	Neurological Disease
Lu AE98134, an activator of voltage-gated sodium channels, acts as a partly selective Na_v1.1 channels positive modulator. Lu AE98134 also increases the activity of Na_v1.2 and Na_v1.5 channels but not of Na_v1.4, Na_v1.6 and Na_v1.7 channels. Lu AE98134 can be used to analyze pathophysiological functions of the Na_v1.1 channel in various central nervous system diseases, including cognitive restoring in schizophrenia, et al .

HY-146069

ABBV-318	Sodium Channel	Neurological Disease
ABBV-318 is a potent **Nav1.7/ Nav1.8 blocker, with IC₅₀s of 2.8 μM and 3.8 μM for hNav1.7 and hNav1.8**, respectively. ABBV-318 can be used for the research of pain .

HY-122001

PF-05186462	Sodium Channel	Neurological Disease
PF-05186462 is a potent and selective inhibitor of *human Nav1.7 voltage-dependent sodium channel, with an IC₅₀* of 21 nM. PF-05186462 shows significant selectivity for Nav1.7 versus other sodium channels (Nav 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, and 1.8). PF-05186462 can be used for the research of acute or chronic pain .

HY-178281

E0199	Potassium Channel Sodium Channel	Neurological Disease
E0199 is a novel potent dual-target *K_V7/Na_V* modulator that activates the K_V7 channel (K_V7.2/7.3 (EC₅₀ = 12.78 nM), K_V7.2 (EC₅₀ = 0.50 μM), and K_V7.5 (EC₅₀ = 27.14 nM) channels) while simultaneously blocks the Na_V1.7 (IC₅₀ = 0.52 μM), Na_V1.8 (IC₅₀ = 0.24 μM), and Na_V1.9 (IC₅₀ = 0.16 μM) channels. E0199 shows a potent analgesic effect without affecting heart and skeletal muscle ion channels critically in a chronic constriction injury (CCI) mouse model. E0199 can be used for Neuropathic pain (NP) research .

HY-128772

XPC-6444 1 Publications Verification	Sodium Channel	Neurological Disease
XPC-6444 is a highly potent, isoform-selective, and CNS-penetrant *Na_V1.6* inhibitor (IC₅₀=41 nM for hNa_V1.6). XPC-6444 also displays potent block of Na_V1.2 (IC₅₀=125 nM). XPC-6444 shows anticonvulsant activity .

HY-178494

Nav1.7-IN-19	Sodium Channel Potassium Channel	Neurological Disease
Nav1.7-IN-19 is a potent, selective and orally active *Nav1.7* inhibitor with an IC₅₀ of 0.49 μM. Nav1.7-IN-19 shows high selectivity for Nav1.7, with selectivities of 312-fold and 662-fold against Nav1.1 and Nav1.5 in the inactivated state. Nav1.7-IN-19 exhibits weak inhibition on hERG potassium channels. Nav1.7-IN-19 exhibits analgesic effect and can be used for the research of neurological disease .

HY-178963

Nav1.2-IN-2	Sodium Channel Calcium Channel	Neurological Disease
Nav1.2-IN-2 is a *Nav1.2* inhibitor with a human IC₅₀ of 0.18 μM. Nav1.2-IN-2 preferentially binds to the inactivated state of Nav1.2, reduces window current, suppresses neuronal depolarization and action potential generation. Nav1.2-IN-2 suppresses Veratridine (HY-N6691)-induced Ca ²⁺ influx. Nav1.2-IN-2 can be used for the research of epilepsy .

HY-19366

Nav1.7-IN-2	Sodium Channel	Neurological Disease
Nav1.7-IN-2 is an inhibitor of voltage-gated sodium channels (Nav), in particular Nav 1.7, with IC50 of 80 nM.

HY-155635

Nav1.8-IN-4	Sodium Channel	Infection
Nav1.8-IN-4 (compound 9a) is a *Nav1.8* channel inhibitor (IC₅₀=0.014 μM). Nav1.8-IN-4 can be used for research on pain-related diseases .

HY-126429

Nav1.1 activator 1	Sodium Channel	Neurological Disease
Nav1.1 activator 1 (compound 4), a highly potent *Na_v1.1* activator with BBB penetration, increases decay time constant τ of Na_v1.1 currents at 0.03 μM along with significant selectivity against Na_v1.2, Na_v1.5, and Na_v1.6 .

HY-157784

XPC-7724	Sodium Channel	Neurological Disease
XPC-7724 is a selective *Na_v1.6* channel inhibitor with a IC₅₀ value of 0.078 μM. XPC-7724 can be used in the study of neurological diseases .

HY-103623

PF-05241328	Sodium Channel	Neurological Disease
PF-05241328 is a potent and selective inhibitor of human Nav1.7 voltage-dependent sodium channels *(Nav1.7), with an IC₅₀* of 31 nM.

HY-100727

AM-2099 1 Publications Verification	Sodium Channel	Neurological Disease
AM-2099 is a potent and selective inhibitor of voltage-gated sodium channel *Nav1.7* with an IC₅₀ of 0.16 μM for human Nav1.7.

HY-P1073

ProTx-I	Calcium Channel Potassium Channel Sodium Channel TRP Channel	Neurological Disease Cancer
ProTx-I is a toxin derived from Thrixopelma pruriens and a peptide inhibitor targeting TTX-resistant sodium channels. ProTx-I interacts with voltage sensors of multiple domains such as *NaV1.7, reduces neuronal excitability through allosteric modulation of channel gating and alteration of voltage dependence. The IC₅₀* values of ProTx-I against human *NaV1.7, NaV1.2, NaV1.6, and NaV1.5* are 95 nM, 104 nM, 21 nM, and 358 nM, respectively; ProTx-I also potently inhibits Ba ²⁺ currents of hCav3.1, while its inhibitory potency against hCav3.2 is approximately 160-fold lower. ProTx-I is applicable to the research of chronic pain .

HY-P1220A

Huwentoxin-IV TFA	Sodium Channel	Neurological Disease
Huwentoxin-IV TFA is a potent and selective sodium channel blocker, inhibits neuronal *Nav1.7, Nav1.2, Nav1.3* and *Nav1.4* with IC₅₀s of 26, 150, 338 and 400 nM, respectively. Huwentoxin-IV TFA preferentially blocks peripheral nerve subtype Nav1.7 by binding neurotoxin receptor site 4. Huwentoxin-IV TFA has analgesic effects on animal models of inflammatory and neuropathic pain .

HY-P5786

Heteropodatoxin-1 HpTx1	Potassium Channel Sodium Channel	Neurological Disease
Heteropodatoxin-1 (HpTx1), a spider peptide toxin, is a Kv4.2 current inhibitor. Heteropodatoxin-1 also inhibits *Nav1.7* and activates *Nav1.9* but does not affect Nav1.8 .

HY-P1218B

Phrixotoxin 3-NH2 TFA	Sodium Channel	Neurological Disease
Phrixotoxin 3-NH2 TFA is a derivative of Phrixotoxin 3 TFA (HY-P1218A). Phrixotoxin 3 TFA is a potent blocker of voltage-gated sodium channels, with IC₅₀s of 0.6, 42, 72, 288, 610 nM for *NaV1.2, NaV1.3, NaV1.4, NaV1.1* and *NaV1.5*, respectively. Phrixotoxin 3 TFA modulates voltage-gated sodium channels with properties similar to those of typical gating-modifier toxins, both by causing a depolarizing shift in gating kinetics and by blocking the inward component of the sodium current .

HY-16723A

(R)-Funapide (R)-TV 45070; (R)-XEN402	Sodium Channel	Neurological Disease Inflammation/Immunology
(R)-Funapide ((R)-TV 45070) is the less active R-enantiomer of Funapide. Funapide is a potent inhibitor of the sodium channel *Nav1.7, Nav1.8* and other Nav channels expressed in the peripheral nervous system. Fornabil is an orally effective analgesic agent .

HY-P10234A

Poneratoxin acetate 3 Publications Verification	Sodium Channel	Neurological Disease
Poneratoxin acetate is the acetate salt form of Poneratoxin (HY-P10234). Poneratoxin acetate is the modulator for voltage-gated sodium channel (NaV, EC₅₀ for NaV1.6 and NaV1.7 is 97 nM and 2.3 µM), that lowers the voltage threshold for activation and inhibits the inactivation of channels, enhances the excitability of neurons, and leads to the transmission of pain signals .

HY-132133

Nav1.8-IN-1	Sodium Channel	Neurological Disease Inflammation/Immunology
Nav1.8-IN-1 (Compound 31) is a potent inhibitor of Na(v)1.8 sodium channel. Nav1.8-IN-1 has the potential for the research of inflammatory and neuropathic pain .

HY-155058

Nav1.3 channel inhibitor 1	Sodium Channel	Neurological Disease
Nav1.3 channel inhibitor 1 (compound 15b) is a state-dependent voltage-gated sodium channel Na_v1.3 inhibitor (IC₅₀=20 nM). Nav1.3 channel inhibitor 1 can penetrate the blood-brain barrier and can be used in the research of nervous system diseases .

HY-P990503

*Anti-SCN9a/Nav1.7 Antibody*	Sodium Channel	Inflammation/Immunology
Anti-SCN9a/Nav1.7 Antibody is a human antibody expressed in CHO, targeting *SCN9a/Nav1.7. Anti-SCN9a/Nav1.7 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-SCN9a/Nav*1.7 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P1218

Phrixotoxin 3	Sodium Channel	Neurological Disease
Phrixotoxin 3 is a potent blocker of voltage-gated sodium channels, with IC₅₀s of 0.6, 42, 72, 288, 610 nM for *NaV1.2, NaV1.3, NaV1.4, NaV1.1* and *NaV1.5*, respectively. Phrixotoxin 3 modulates voltage-gated sodium channels with properties similar to those of typical gating-modifier toxins, both by causing a depolarizing shift in gating kinetics and by blocking the inward component of the sodium current .

HY-P5781

δ-Theraphotoxin-Hm1b	Sodium Channel	Neurological Disease
δ-Theraphotoxin-Hm1b is a 42-amino acid peptide isolated from Togo starburst tarantula (Heteroscodra maculata) venom. δ-Theraphotoxin-Hm1b selectively inhibits inactivation of *NaV1.1* but have no effect on NaV1.7 .

HY-172903

Nav1.8-IN-16	Sodium Channel	Neurological Disease Inflammation/Immunology
Nav1.8-IN-16 (Compound (R)-40) is an orally active and selective hNaV 1.8 inhibitor (IC₅₀: 5.9 nM). Nav1.8-IN-16 exerts analgesic effects by blocking NaV1.8 channels without significantly affecting other NaV subtypes or hERG channels. Nav1.8-IN-16 exhibits dose-dependent analgesic effects in postoperative pain and inflammatory pain models and can be used in pain-related research .

HY-118048

NAV 26	Sodium Channel	Neurological Disease
NAV 26 (Compound 26) is a selective *Na_V1.7* inhibitor with an IC₅₀ of 0.37 μM. NAV 26 is applicable for pain-related research .

HY-159094

Nav1.8-IN-15	Sodium Channel	Neurological Disease
Nav1.8-IN-15 (compound 6) is a potent *Nav1.8* inhibitor. Nav1.8-IN-15 shows analgesic effect. Nav1.8-IN-15 has the potential for the research of chronic pain .

HY-160591

Nav1.8-IN-10	Sodium Channel	Neurological Disease
Nav1.8-IN-10 (Compound 6) is a *Nav1.8* channel inhibitor. When the concentration is 4 nM, the percentage blocking rate of Nav1.8 channel is 79.4%. Nav1.8-IN-10 can be used in the study of pain disorders .

HY-172998

Nav1.8-IN-18	Sodium Channel	Neurological Disease
Nav1.8-IN-19 (Compound 70) is a *Nav1.8* inhibitor.

HY-172999

Nav1.8-IN-19	Sodium Channel	Neurological Disease
Nav1.8-IN-19 (Compound 122) is a *Nav1.8* inhibitor with an IC₅₀ of 0.44 nM in HEK cells. Nav1.8-IN-19 can be used for the study of pain .

HY-160592

Nav1.8-IN-11	Sodium Channel	Neurological Disease
Nav1.8-IN-11 (Example 1) is a *Nav1.8* channel inhibitor with a IC₅₀ value of 0.1 nM. Nav1.8-IN-11 can be used in the study of pain disorders .

HY-176065

Nav1.2-IN-1	Sodium Channel	Neurological Disease
Nav1.2-IN-1 (compound 5i), a 3-(1,2,3,6-tetrahydropyridine)-4-azaindole derivative, is a potent and selective *Nav1.2* inhibitor. Nav1.2-IN-1 induces a reduction in the peak amplitude of Nav1.2 currents with an IC₅₀ value of 7.79 μM. Nav1.2-IN-1 exhibits antiepileptic activity. Nav1.2-IN-1 shows high anticonvulsant effect and low neurotoxicity in subcutaneous Pentetrazole (sc-PTZ)-induced epilepsy mode .

HY-161572

Nav1.8-IN-13	Sodium Channel	Cardiovascular Disease
Nav1.8-IN-13 (compound 16) is a Nav1.8 inhibitor (pIC₅₀=7.9) .

Cat. No.	Product Name

HY-L923

Ion Channel Lead-like Compound Library

9000 compounds

Ion channels are key proteins on the cell membrane that regulate the flow of ions across membranes. They participate in nearly all physiological processes, including nerve conduction, muscle contraction, heart rhythm, and pain perception. Abnormalities in their function can lead to various serious diseases such as arrhythmia, epilepsy, hypertension, neuropathic pain, and cancer. Therefore, ion channels are highly valuable drug targets—over 15% of approved drugs target ion channels currently, demonstrating their irreplaceable therapeutic value in cardiovascular, neurological, and analgesic fields.

MCE has collected a library of over 5,000 reported ion channel-related bioactive compounds targeting major sites such as Na+ channels, K+ channels, Ca2+ channels, GABA receptors, iGluRs, and others. Using AI models, these compounds are characterized through both 2D representations (molecular fingerprints, pharmacophores) and 3D representations (3D conformation) to screen for a collection of lead-like compounds highly similar to known active molecules. Additionally, an hERG channel prediction algorithm integrating XGB and ISE mapping strategy is employed to assess and exclude potential cardiotoxicity in the library.. This step significantly reduces safety risks in subsequent screenings, particularly for ion channel drug development related to cardiovascular systems (e.g., Nav1.5, Cav1.2), effectively minimizing failures due to hERG inhibition and serving as a valuable tool for ion channel drug screening.

HY-L118

Sodium Channel Blocker Library

187 compounds

Sodium channels conduct sodium ions (Na+) through a cell's plasma membrane that are the source of excitatory currents for the nervous system and muscle. Na channels are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (Voltage-gated, voltage-sensitive, or voltage-dependent sodium channel also called VGSCs or Nav channel) or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels). Dysfunction in voltage-gated sodium channels correlates with neurological and cardiac diseases, including epilepsy, myopathies, pain and cardiac arrhythmias. Sodium channel blockers are used in the treatment of cardiac arrhythmia, pain and convulsion.

MCE offers a unique collection of 187 sodium channel blocker and antagonists, all of which have the identified inhibitory effect on sodium channels. MCE Sodium Channel Blocker Library can be used for neurological and cardiac diseases drug discovery and sodium channel research.

Cat. No.	Product Name	Target	Research Area

HY-P1221A

ProTx II TFA	Sodium Channel	Neurological Disease
ProTx II TFA is a selective blocker of Nav1.7 sodium channels with an IC₅₀ of 0.3 nM, and is at least 100-fold selective for Nav1.7 over other sodium channel subtypes. ProTx-II inhibits sodium channels by decreasing channel conductance and shifting activation to more positive potentials and blocks action potential propagation in nociceptors .

HY-P1073

ProTx-I	Calcium Channel Potassium Channel Sodium Channel TRP Channel	Neurological Disease Cancer
ProTx-I is a toxin derived from Thrixopelma pruriens and a peptide inhibitor targeting TTX-resistant sodium channels. ProTx-I interacts with voltage sensors of multiple domains such as *NaV1.7, reduces neuronal excitability through allosteric modulation of channel gating and alteration of voltage dependence. The IC₅₀* values of ProTx-I against human *NaV1.7, NaV1.2, NaV1.6, and NaV1.5* are 95 nM, 104 nM, 21 nM, and 358 nM, respectively; ProTx-I also potently inhibits Ba ²⁺ currents of hCav3.1, while its inhibitory potency against hCav3.2 is approximately 160-fold lower. ProTx-I is applicable to the research of chronic pain .

HY-P1443

OD1	Sodium Channel	Cancer
OD1 is a scorpion α-toxin that can be isolated from the venom of the Iranian yellow scorpion (Odonthobuthus doriae. OD1 is a modulator of mammalian *Nav1.7* (EC₅₀: 4.5 nM) .

HY-P1220A

Huwentoxin-IV TFA	Sodium Channel	Neurological Disease
Huwentoxin-IV TFA is a potent and selective sodium channel blocker, inhibits neuronal *Nav1.7, Nav1.2, Nav1.3* and *Nav1.4* with IC₅₀s of 26, 150, 338 and 400 nM, respectively. Huwentoxin-IV TFA preferentially blocks peripheral nerve subtype Nav1.7 by binding neurotoxin receptor site 4. Huwentoxin-IV TFA has analgesic effects on animal models of inflammatory and neuropathic pain .

HY-P5786

Heteropodatoxin-1 HpTx1	Potassium Channel Sodium Channel	Neurological Disease
Heteropodatoxin-1 (HpTx1), a spider peptide toxin, is a Kv4.2 current inhibitor. Heteropodatoxin-1 also inhibits *Nav1.7* and activates *Nav1.9* but does not affect Nav1.8 .

HY-P1218B

Phrixotoxin 3-NH2 TFA	Sodium Channel	Neurological Disease
Phrixotoxin 3-NH2 TFA is a derivative of Phrixotoxin 3 TFA (HY-P1218A). Phrixotoxin 3 TFA is a potent blocker of voltage-gated sodium channels, with IC₅₀s of 0.6, 42, 72, 288, 610 nM for *NaV1.2, NaV1.3, NaV1.4, NaV1.1* and *NaV1.5*, respectively. Phrixotoxin 3 TFA modulates voltage-gated sodium channels with properties similar to those of typical gating-modifier toxins, both by causing a depolarizing shift in gating kinetics and by blocking the inward component of the sodium current .

HY-P10234A

Poneratoxin acetate 3 Publications Verification	Sodium Channel	Neurological Disease
Poneratoxin acetate is the acetate salt form of Poneratoxin (HY-P10234). Poneratoxin acetate is the modulator for voltage-gated sodium channel (NaV, EC₅₀ for NaV1.6 and NaV1.7 is 97 nM and 2.3 µM), that lowers the voltage threshold for activation and inhibits the inactivation of channels, enhances the excitability of neurons, and leads to the transmission of pain signals .

HY-P1221

ProTx II	Sodium Channel	Neurological Disease
ProTx II is a selective blocker of Nav1.7 sodium channels with an IC₅₀ of 0.3 nM, and is at least 100-fold selective for Nav1.7 over other sodium channel subtypes. ProTx-II inhibits sodium channels by decreasing channel conductance and shifting activation to more positive potentials and blocks action potential propagation in nociceptors .

HY-P5152

Scorpion toxin Tf2	Sodium Channel	Neurological Disease
Scorpion toxin Tf2 is a β-scorpion toxin, which is firstly identified in the venom of the Brazilian scorpion Tityus fasciolatus. Scorpion toxin Tf2 is a *Nav1.3* activator, which is a neuronal voltage-gated sodium (Nav) subtype implicated in epilepsy and nociception. Scorpion toxin Tf2 enhances hNav1.3 activation voltage and opens the channel at resting membrane potentials .

HY-P5807A

Cn2 toxin TFA β-Mammal toxin Cn2 TFA	Sodium Channel	Neurological Disease
Cn2 toxin TFA (β-Mammal toxin Cn2 TFA) is a single-chain β-scorpion neurotoxic peptide that is the main toxin in scorpion venom. Cn2 toxin (TFA) specifically targets mammalian voltage-gated sodium channels (VGSC) Nav1.6 .

HY-P1218

Phrixotoxin 3	Sodium Channel	Neurological Disease
Phrixotoxin 3 is a potent blocker of voltage-gated sodium channels, with IC₅₀s of 0.6, 42, 72, 288, 610 nM for *NaV1.2, NaV1.3, NaV1.4, NaV1.1* and *NaV1.5*, respectively. Phrixotoxin 3 modulates voltage-gated sodium channels with properties similar to those of typical gating-modifier toxins, both by causing a depolarizing shift in gating kinetics and by blocking the inward component of the sodium current .

HY-P5781

δ-Theraphotoxin-Hm1b	Sodium Channel	Neurological Disease
δ-Theraphotoxin-Hm1b is a 42-amino acid peptide isolated from Togo starburst tarantula (Heteroscodra maculata) venom. δ-Theraphotoxin-Hm1b selectively inhibits inactivation of *NaV1.1* but have no effect on NaV1.7 .

HY-P5809

Pe1b μ-TrTx-Pe1b	Sodium Channel	Neurological Disease
Pe1b (μ-TrTx-Pe1b) is a selective *Na_v1.7* inhibitor with an IC₅₀ of 167 nM .

HY-P11045

JNJ63955918	Sodium Channel	Neurological Disease
JNJ63955918 is a potent, highly selective, blocked-state *Nav1.7* blocking peptide with an IC₅₀ of 8.0 nM. JNJ63955918 can be used in pain research .

HY-P5160A

Phlotoxin-1 TFA PhlTx1 TFA	Sodium Channel	Neurological Disease
Phlotoxin-1 (PhlTx1) is a 34-amino acid and 3-disulfide bridge peptide. Phlotoxin-1 can be isolated from Phlogiellus genus spider. Phlotoxin-1 is an antinociceptive agent by inhibiting *NaV1.7* channel .

HY-P5807

Cn2 toxin β-Mammal toxin Cn2	Sodium Channel	Neurological Disease
Cn2 toxin is aβ- toxoins. Cn2 toxin can bind to the voltage sensing domain of voltage gated sodium channels (Na_v) .

HY-P5795

GsAF-I	Sodium Channel Potassium Channel	Neurological Disease
GsAF-I is a potent *Na_v* and hERG1 channels blocker with IC₅₀s of 0.36, 0.6, 1.28, 0.33, 1.2, 0.04 and 4.8 μM against Na_v1.1, Na_v1.2, Na_v1.3, Na_v1.4, Na_v1.6, Na_v1.7 and hERG1, respectively .

HY-P1220

Huwentoxin-IV	Sodium Channel	Neurological Disease
Huwentoxin-IV is a potent and selective sodium channel blocker, inhibits neuronal *Nav1.7, Nav1.2, Nav1.3* and *Nav1.4* with IC₅₀s of 26, 150, 338 and 400 nM, respectively. Huwentoxin-IV preferentially blocks peripheral nerve subtype Nav1.7 by binding neurotoxin receptor site 4. Huwentoxin-IV has analgesic effects on animal models of inflammatory and neuropathic pain .

HY-P5811

Ceratotoxin-1 CcoTx1; β-TRTX-cm1a	Sodium Channel	Neurological Disease
Ceratotoxin-1 (CcoTx1), a peptide toxin, is an voltage-gated sodium channel subtypes inhibitor. Ceratotoxin-1 inhibits *Nav1.1/β1, Nav1.2/β1, Nav1.4/β1, and Nav1.5/β1* with IC₅₀ of 523 nM, 3 nM, 888 nM, and 323 nM, respectively. Ceratotoxin-1 also inhibits *Nav1.8/β1* .

HY-P10234

Poneratoxin	Sodium Channel	Neurological Disease
Poneratoxin is the modulator for voltage-gated sodium channel (NaV, EC₅₀ for NaV1.6 and NaV1.7 is 97 nM and 2.3 µM), that lowers the voltage threshold for activation and inhibits the inactivation of channels, enhances the excitability of neurons, and leads to the transmission of pain signals .

HY-P1681A

GpTx-1 TFA	Sodium Channel	Neurological Disease
GpTx-1 TFA is a peptide-based *Na_V1.7* sodium channel antagonist isolated from the venom of the Chilean spider Grammostola porter. GpTx-1 TFA demonstrates potent inhibitory activity against the *Na_V1.7* channel with an IC₅₀ value of 10 nM, while exhibiting excellent selectivity for *Na_V1.4* (IC₅₀ = 0.301 μM) and *Na_V1.5* (IC₅₀ = 4.20 μM), showing >20-fold and >950-fold selectivity respectively .

HY-P1681

GpTx-1	Sodium Channel	Neurological Disease
GpTx-1 is a peptide-based *Na_V1.7* sodium channel antagonist isolated from the venom of the Chilean spider Grammostola porter. GpTx-1 demonstrates potent inhibitory activity against the *Na_V1.7* channel with an IC₅₀ value of 10 nM, while exhibiting excellent selectivity for *Na_V1.4* (IC₅₀ = 0.301 μM) and *Na_V1.5* (IC₅₀ = 4.20 μM), showing >20-fold and >950-fold selectivity respectively .

HY-P1219

Jingzhaotoxin-III β-TRTX-Cj1α	Sodium Channel	Neurological Disease
Jingzhaotoxin-III is a potent and selective blocker of Nav1.5 channels, with an IC₅₀ of 348 nM, and shows no effect on other sodium channel isoforms. Jingzhaotoxin-III can selectively inhibit the activation of cardiac sodium channel but not neuronal subtypes, and hopefully represents an important ligand for discriminating cardiac VGSC subtype .

HY-P5916

VSTx-3 κ-Theraphotoxin-Gr4a; Kappa-TRTX-Gr4a; Voltage sensor toxin 3; Peptide F	Peptides Potassium Channel	Neurological Disease
VSTx-3 is a K_V channel blocker. VSTx-3 is demonstrated to be a potent, TTX-sensitive sodium channel blocker and especially, a potent blocker of NaV1.8 channels (IC₅₀ 0.19 μM for hNaV1.3, 0.43 μM for hNaV1.7 and 0.77 μM for hNaV1.8 channels).

HY-P5900

m3-Huwentoxin IV m3-HwTx-IV	Sodium Channel	Neurological Disease
m3-Huwentoxin IV (m3-HwTx-IV) is a potent *Na_V* inhibitor with IC₅₀s of 3.3, 6.8, 7.2, 8.4, 11.9 and 369 nM against hNa_V1.7, hNa_V1.6, hNa_V1.3, hNa_V1.1, hNa_V1.2 and hNa_V1.4, respectively in QPatch assay. m3-Huwentoxin IV dose-dependently suppresses spontaneous pain induced by the Na_V1.7 activator OD1 in a rodent pain model .

HY-P1441A

Mambalgin 1 TFA	Sodium Channel	Neurological Disease
Mambalgin 1 TFA is a selective ASIC1a inhibitor (IC₅₀ values are 192 and 72 nM for human ASIC1a and ASIC1a/1b dimer, respectively). Mambalgin 1 TFA binds to closed/inactive channel. Mambalgin 1 TFA is selective for ASIC1a over ASIC2a, ASIC3, TRPV1, P2X2, 5-HT3, Nav1.8, Cav3.2 and Kv1.2 channels. Mambalgin 1 TFA increases latency of withdrawal response in mouse tail-flick and paw-flick tests.

HY-P5790

μ-TRTX-Hd1a	Sodium Channel	Neurological Disease
μ-TRTX-Hd1a, a spider venom, is a selective NaV 1.7 inhibitor. μ-TRTX-Hd1a is a gating modifier that inhibits human NaV 1.7 by interacting with the S3b-S4 paddle motif in channel domain II .

HY-P5164

GrTx1	Sodium Channel	Neurological Disease
GrTx1 is a peptide toxin originally isolated from the venom of the spider Grammostola rosea. GrTx1 blocks sodium channel, with IC₅₀s of 0.63 μM, 0.23 μM, 0.77 μM, 1.29 μM, 0.63 μM and 0.37 μM for Nav1.1, Nav1.2, Nav1.3, Nav1.4, Nav1.6 and Nav1.7, repectively . GrTx1 can be used for neurological disease research .

HY-P1218A

Phrixotoxin 3 TFA	Sodium Channel	Neurological Disease
Phrixotoxin 3 TFA is a potent blocker of voltage-gated sodium channels, with IC₅₀s of 0.6, 42, 72, 288, 610 nM for *NaV1.2, NaV1.3, NaV1.4, NaV1.1* and *NaV1.5*, respectively. Phrixotoxin 3 TFA modulates voltage-gated sodium channels with properties similar to those of typical gating-modifier toxins, both by causing a depolarizing shift in gating kinetics and by blocking the inward component of the sodium current .

HY-P5801

Phlo1a μ-TrTx-Phlo1a	Sodium Channel	Neurological Disease
Phlo1a (μ-TrTx-Phlo1a) is a peptide toxin contains 35-amino acid residues. Phlo1b is a selective *Nav1.7* inhibitor. Phlo1a has a weak inhibitory effect on Nav1.2 and Nav1.5 .

HY-P5800

Phlo1b μ-TrTx-Phlo1b	Sodium Channel	Neurological Disease
Phlo1b (μ-TrTx-Phlo1b) is a peptide toxin contains 35-amino acid residues. Phlo1b is a selective *Nav1.7* inhibitor. Phlo1b has a weak inhibitory effect on Nav1.2 and Nav1.5 .

HY-P5793

GTx1-15	Sodium Channel Calcium Channel	Neurological Disease
GTx1-15 is an inhibitor cystine knot (ICK) peptide that inhibits the voltage-dependent calcium channel Cav3.1 and the voltage-dependent sodium channels Nav1.3 and *Nav1.7* .

HY-P5865

Tap1a Theraphotoxin-Tap1a; TRTX-Tap1a; µ/ω-TRTX-Tap1a	Sodium Channel	Neurological Disease
Tap1a (Theraphotoxin-Tap1a) is a spider venom peptide that inhibits sodium channels with IC₅₀s of 80 nM and 301 nM against Na_v1.7 and Na_v1.1, respectively. Tap1a shows analgesic effects .

HY-P5810

Ceratotoxin-2 CcoTx2; β-TRTX-cm1b	Sodium Channel	Neurological Disease
Ceratotoxin-2 (CcoTx2) is a voltage-gated sodium channel blocker with IC₅₀s of 8 nM and 88 nM against Na_v1.2/β₁ and Na_v1.3/β₁, respectively .

HY-P5177

GsAF-II	Sodium Channel Potassium Channel	Neurological Disease
GsAF-II is a peptide toxin that blocks hERG1 subtype potassium channels in a voltage-dependent manner. GsAF-II blocks Nav1.x subtype sodium channels .

HY-P5784

δ-Buthitoxin-Hj1a	Sodium Channel	Neurological Disease
δ-Buthitoxin-Hj1a, a scorpion-venom peptide, is a potent *NaV1.1* agonist with an EC₅₀ of 17nM. δ-Buthitoxin-Hj1a can be used for the Dravet syndrome (DS) research .

HY-P5783

δ-Buthitoxin-Hj2a	Sodium Channel	Neurological Disease
δ-Buthitoxin-Hj2a, a scorpion-venom peptide, is a potent *NaV1.1* agonist with an EC₅₀ of 32 nM. δ-Buthitoxin-Hj2a can be used for the Dravet syndrome (DS) research .

HY-P5160

Phlotoxin-1 PhlTx1	Sodium Channel	Neurological Disease
Phlotoxin-1 (PhlTx1) is a 34-amino acid and 3-disulfide bridge peptide. Phlotoxin-1 can be isolated from Phlogiellus genus spider. Phlotoxin-1 is an antinociceptive agent by inhibiting *NaV1.7* channel .

HY-P5872

Jingzhaotoxin XI JZTX-XI	Sodium Channel	Neurological Disease
Jingzhaotoxin XI (JZTX-XI) is a sodium conductance inhibitor with an IC₅₀ of 124 nM. Jingzhaotoxin XI slows the fast inactivation (EC₅₀=1.18±0.2 μM) of Na_v1.5 expressed in Chinese hamster ovary (CHO-K1) cells .

HY-P5782

δ-Theraphotoxin-Hm1a toxin	Sodium Channel	Neurological Disease
δ-Theraphotoxin-Hm1a toxin is a selective *Na_v1.1* activator. δ-Theraphotoxin-Hm1a toxin elicits pain and touch sensitivity. δ-Theraphotoxin-Hm1a toxin can be used for the research of irritable bowel syndrome .

HY-P5813

Cd1a β-TRTX-cd1a; β-Theraphotoxin-cd1a	Calcium Channel	Neurological Disease
Cd1a is a β-toxin derived from the African spider Ceratogyrus darlingi. Cd1a can regulate calcium ion channels. Cd1a inhibits human calcium ion channels (Ca_v2.2)(IC₅₀2.6 μM) and mouse sodium ion channels (Na_v1.7). Cd1a can be used in the development of peripheral pain treatment drugs .

HY-P5153

ProTx-III μ-TRTX-Tp1a	Sodium Channel	Neurological Disease
ProTx-III is a selective and potent inhibitor of voltage-gated sodium channel *Na_v1.7, with an IC₅₀* of 2.1 nM. ProTx-III is a spider venom peptide isolated from the venom of the Peruvian green velvet tarantella. ProTx-III has a typical inhibitor cystine knot motif (ICK). ProTx-III is able to reverse the pain response. ProTx-III can be used to study diseases such as chronic pain, epilepsy, and arrhythmia .

HY-P5162

Dc1a	Sodium Channel	Inflammation/Immunology
Dc1a potently promotes opening of the German cockroach Na_v channel (BgNa_v1). Dc1a is a toxin can be isolated from the desert bush spider Diguetia canities .

Cat. No.	Product Name	Target	Research Area	Image

HY-P990503

*Anti-SCN9a/Nav1.7 Antibody*	Sodium Channel	Inflammation/Immunology
Anti-SCN9a/Nav1.7 Antibody is a human antibody expressed in CHO, targeting *SCN9a/Nav1.7. Anti-SCN9a/Nav1.7 Antibody has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-SCN9a/Nav*1.7 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990502

*Anti-SCN11a/Nav1.9 Antibody*	Sodium Channel	Inflammation/Immunology
The Anti-SCN11a/Nav1.9 Antibody is a CHO-expressed human antibody that targets *SCN11a/Nav1.9. The Anti-SCN11a/Nav1.9 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.94 kDa. The isotype control for the Anti-SCN11a/Nav*1.9 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991902

NAV006	CD20	Cancer
NAV006 is an anti-CD20 antibody variant of Rituximab (HY-P9913) with a K_dof 30.5 nM to CD20. NAV006 exhibits reduced interaction with CA125 and demonstrates enhanced antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activity. NAV006 displays antitumor activity against lymphoma and can be used in research on non-Hodgkin lymphoma .

HY-P992420

NAV-001 Antibody

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6691

Veratridine 4 Publications Verification 3-Veratroylveracevine	Alkaloids Veratrum nigrum Linn. Liliaceae Plants Isoquinoline Alkaloids Source Classification	Sodium Channel
Veratridine (3-Veratroylveracevine) is a plant neurotoxin, a voltage-gated sodium channels (VGSCs) agonist. Veratridine inhibits the peak current of Nav1.7, with an IC₅₀ of 18.39 µM. Veratridine regulates sodium ion channels mainly by activating sodium ion channels, preventing channel inactivation and increasing sodium ion flow .

HY-N0478

Neoline 1 Publications Verification Bullatine B	Alkaloids Piperidine Alkaloids other families Plants Source Classification	Others
Neoline (Bullatine B) is the active ingredient of the active ingredient (PA), which can be used to cure the disease. Neoline Flow Suppression Nav1.7 Electrical Flow Control (VGSC), improve diabetes mechanical pain sensitivity. Neoline has a list of compounds that can be used, research on its use, and the quality of its processing during processing in pain .

HY-N1847

3'-Methoxydaidzein	Flavonoids Leguminosae Maackia amurensis Rupr. et Maxim. Plants Isoflavones Source Classification	Sodium Channel
3'-Methoxydaidzein is a isoflavone and a Sodium Channel inhibitor. 3'-Methoxydaidzein inhibits subtypes NaV1.7, NaV1.8 and NaV1.3 with IC₅₀ of 181 nM, 397 nM, and 505 nM, respectively. 3'-Methoxydaidzein exerts analgesic activity by inhibiting voltage-gated sodium channels .

HY-N6691R

Veratridine (Standard) 3-Veratroylveracevine (Standard)	Alkaloids Structural Classification Veratrum nigrum Linn. Liliaceae Plants Isoquinoline Alkaloids Source Classification	Reference Standards Sodium Channel
Veratridine (Standard) is the analytical standard of Veratridine. This product is intended for research and analytical applications. Veratridine (3-Veratroylveracevine) is a plant neurotoxin, a voltage-gated sodium channels (VGSCs) agonist. Veratridine inhibits the peak current of Nav1.7, with an IC₅₀ of 18.39?μM. Veratridine regulates sodium ion channels mainly by activating sodium ion channels, preventing channel inactivation and increasing sodium ion flow .

HY-155236

Ancistrotecine B	Alkaloids Piperidine Alkaloids Ancistrocladus tectorius (Lour.) Merr. Plants Ancistrocladaceae Source Classification	Sodium Channel
Ancistrotecine B (Compound 2) is a *Nav1.7* channel inhibitor (IC₅₀: 0.73 μM). Ancistrotecine B relieves inflammatory pain in mice .

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P703462

	*VSD4-NaV1.7-NaVPas Protein, Human (HEK293, Flag, Strep)* NENA	Human	HEK293
	VSD4-NaV1.7-NaVPas Protein, Human (HEK293, Flag, Strep) is the recombinant human-derived VSD4-NaV1.7-NaVPas, expressed by HEK293 , with Strep, Flag labeled tag. ,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-W052508S

Norquetiapine-d8

Norquetiapine-d8 (N-Desalkylquetiapine-d8) is the deuterium labeled Norquetiapine.Norquetiapine ( N-Desalkylauetiapine), a metabolite of Quetiapine (HY-14544), is a selective HCN1 channel inhibitor, with an IC₅₀ of 13.9 μM. Norquetiapine selectively inhibits noradrenaline reuptake, is a partial 5-HT_1A (K_i = 45 nM) receptor agonist, and acts as an antagonist at presynapticα2 (K_i = 237 nM), 5-HT_2C(K_i = 107 nM), and 5-HT₇ (K_i = 76 nM) receptors. Norquetiapine blocks the human cardiac sodium channel Nav1.5 in a state-dependent manner. Norquetiapine shows partial anti-inflammatory effects in LPS (HY-D1056) injected C57BL/6 mice. Norquetiapine can be used for the study of depression and inflammation .

HY-17355BS

Dexpramipexole-d3 dihydrochloride

Dexpramipexole-d₃ ((R)-Pramipexole-d₃) dihydrochloride is the deuterium labeled Dexpramipexole. Dexpramipexole ((R)-Pramipexole) dihydrochloride is an orally active, blood-brain barrier permeable mitochondrial protective agent. Dexpramipexole dihydrochloride upregulates the expression of Parkin, PINK1, GPX4 and FSP1; binds to mitochondrial F1/Fo-ATP synthase; blocks the Na_v1.8 sodium channel; and inhibits the activation of the NLRP3 inflammasome. Dexpramipexole dihydrochloride induces mitophagy, inhibits ferroptosis, pyroptosis, apoptosis, neuroinflammation and eosinophilopoiesis; maintains mitochondrial function and redox homeostasis; reduces reactive oxygen species production; and decreases myocardial infarct size. Dexpramipexole dihydrochloride is applicable to studies on eosinophilic asthma, myocardial ischemia/reperfusion injury, sepsis-associated encephalopathy, analgesia, and more.

HY-17429S

Flecainide-d4 acetate
Flecainide-d₄ (acetate) is the deuterium labeled Flecainide acetate. Flecainide acetate (R-818) is a class 1C antiarrhythmic agent especially used for the management of supraventricular arrhythmia; works by blocking the Nav1.5 sodium channel in the heart, causing prolongation of the cardiac action potential .

HY-B0262S1

Methocarbamol-d3
Methocarbamol-d₃ is the deuterium labeled Methocarbamol. Methocarbamol is an orally active central muscle relaxant and blocks muscular Nav1.4 channel. Methocarbamol reversibly affects voltage dependence of inactivation of Nav1.4 channel. Methocarbamol has the potential for muscle spasms and pain syndromes research .

HY-B0262S2

Methocarbamol-13C,d3
Methocarbamol- ¹³C,d₃ is the ¹³C- and deuterium labeled Methocarbamol. Methocarbamol is an orally active central muscle relaxant and blocks muscular Nav1.4 channel. Methocarbamol reversibly affects voltage dependence of inactivation of Nav1.4 channel. Methocarbamol has the potential for muscle spasms and pain syndromes research .

HY-B0262S

Methocarbamol-d5
Methocarbamol-d₅ is deuterium labeled Methocarbamol. Methocarbamol is an orally active central muscle relaxant and blocks muscular Nav1.4 channel .

HY-B1837S

Cyfluthrin-d6
Cyfluthrin-d₆ (β-Cyfluthi-d₆) is deuterium labeled Cyfluthrin. Cyfluthrin is a type II pyrethroid and has effects on various insects. Cyfluthrin is a modulator of Nav_1.8 sodium channels by repetitive stimulation. Cyfluthrin can be applied in agriculture,veterinary, insecticide,pyrethroid and stored product .

Cat. No.	Product Name		Classification

HY-148410A

Zorevunersen sodium STK-001 sodium		Antisense Oligonucleotides
Zorevunersen sodium is an antisense oligonucleotide targeting the Scn1a gene based on TANGO technology. Zorevunersen sodium increases Scn1a mRNA transcripts and elevates the expression level of *NaV1.1* protein. Zorevunersen sodium restores the excitability of PV interneurons, thereby reducing seizures and prolonging survival in mice. Zorevunersen sodium can be used for research on Dravet syndrome .

HY-148410

Zorevunersen STK-001		Antisense Oligonucleotides
Zorevunersen is an antisense oligonucleotide targeting the Scn1a gene based on TANGO technology. Zorevunersen increases Scn1a mRNA transcripts and elevates the expression level of *NaV1.1* protein. Zorevunersen restores the excitability of PV interneurons, thereby reducing seizures and prolonging survival in mice. Zorevunersen can be used for research on Dravet syndrome .

HY-148410C

Zorevunensen negative control STK-001 negative control		Antisense Oligonucleotides
Zorevunensen (STK-001) negative control is the negative control form of Zorevunensen (HY-148410). Zorevunensen is an antisense oligonucleotide that is intended to increase the level of productive SCN1A mRNA and consequently increase the expression of the sodium channel *Nav_1.1* protein. Zorevunersen is used for the study of Dravet syndrome .

HY-177629

Elsunersen PRAX-222		Antisense Oligonucleotides
Elsunersen is an antisense oligonucleotide that selectively decreases expression of the gene for the voltage-gated sodium channel Nav1.2 (SCN2A). It is used for the study of SCN2A developmental and epileptic encephalopathy (SCN2A-DEE). SCN2A-DEE is a debi

HY-177629A

Elsunersen sodium PRAX-222 sodium		Antisense Oligonucleotides
Elsunersen sodium is an antisense oligonucleotide that selectively decreases expression of the gene for the voltage-gated sodium channel Nav1.2 (SCN2A). It is used for the study of SCN2A developmental and epileptic encephalopathy (SCN2A-DEE). SCN2A-DEE is

HY-RS09048

NAV3 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
NAV3 Human Pre-designed siRNA Set A contains three designed siRNAs for NAV3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS09047

NAV2 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
NAV2 Human Pre-designed siRNA Set A contains three designed siRNAs for NAV2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS09046

NAV1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
NAV1 Human Pre-designed siRNA Set A contains three designed siRNAs for NAV1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks